IGF-IR ANTAGONISTS AS ADJUVANTS FOR TREATMENT OF PROSTATE CANCER
摘要
The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.
申请公布号
WO2007092453(A2)
申请公布日期
2007.08.16
申请号
WO2007US03164
申请日期
2007.02.03
申请人
IMCLONE SYSTEMS, INC.;LUDWIG, DALE;PLYMATE, STEPHEN, R.